Home > Haematology > Ibrutinib continues to outperform chemoimmunotherapy in patients with treatment-naïve CLL

Ibrutinib continues to outperform chemoimmunotherapy in patients with treatment-naïve CLL

Expert
Dr Jennifer Woyach, Ohio State University, OH, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASH 2021
Trial
Phase 3, Alliance A041202
Ibrutinib was associated with prolonged progression-free survival (PFS) compared to the chemoimmunotherapy regimen bendamustine plus rituximab in older patients with treatment-naïve chronic lymphocytic leukaemia (CLL). In addition, the long-term follow-up data of the phase 3 Alliance A041202 trial (NCT01886872) displayed that ibrutinib therapy may not lead to inferior results in patients with TP53 abnormalities [1]. This is remarkable, since TP53 abnormalities are predictive of worse PFS outcomes in patients with relapsed CLL who are treated with ibrutinib. These findings support the use of ibrutinib-based regimens as a first line of therapy in patients with CLL. Medicom interviewed Dr Jennifer Woyach (Ohio State University, OH, USA), who presented the updated results of the A041202 trial during the


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on